What an inspiring evening of innovation and collaboration! Last Thursday, Eagle IP was honored to once again host the American Intellectual Property Law Association (AIPLA) Women in IP Global Networking Event in Hong Kong, joining forces with hundreds of remarkable women across 40+ global cities.

In the spirit of this year’s theme “Innovation and Collaboration,” we gathered fellow female leaders, innovators, entrepreneurs and IP practitioners to share their amazing career journeys and lessons learnt along the way. We started off the evening with Jennifer Che and Pauli Wong, sharing their paths from scientists that transitioned into an IP career, and what it means to them now to support scientists as IP professionals. We were also privileged to have Dr. Cathy Jim, of RHT Industries Limited, share with us her inspiring journey as a Chemist and Entrepreneur. Cathy recounted how she and her team overcame many difficulties along their path to providing a better solution to real world air quality problems through science. Her one piece of advice and guiding principle? Resilience. At 8PM HKT, we promptly dialed into a joint video call to say hello to hundreds of women at 40+ participating cities around the world holding their own simultaneous events.

To all who joined us: thank you for your lively participation and sharing. Together, we’re not just shaping the future of innovation—we’re redefining what it means to lead. Here’s to many more years of collaboration, growth, and breaking barriers!

Our Past Events

Recommended Insights

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

21 September 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

First ever Invalidation decision on an RNAi Invention patent in China

4 December 2023
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
Top crossarrow-right